Review
Pharmacology & Pharmacy
Wei Wu, Jessica L. Klockow, Michael Zhang, Famyrah Lafortune, Edwin Chang, Linchun Jin, Yang Wu, Heike E. Daldrup-Link
Summary: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor with highly infiltrative nature and treatment resistance, highlighting the importance of innovative treatment strategies. The standard treatment for GBM is surgical resection followed by chemoradiotherapy, but the robust DNA repair and self-renewing capabilities of GBM cells lead to resistance against current therapies.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Engineering, Biomedical
Jiawei Wang, Jiyuan Yang, Jindrich Kopecek
Summary: B cells play multiple roles in immune responses related to autoimmune diseases and cancers, making B cell targeting strategies widely studied. Common mechanisms of B cell targeting therapies include direct B cell depletion, modulation of BCR signaling, targeting B cell survival factors, and immune checkpoint blockade, with nanocarriers playing an important role in B cell-targeted drug delivery.
ACTA BIOMATERIALIA
(2022)
Review
Immunology
Alice Mariottini, Paolo A. Muraro, Jan D. Luenemann
Summary: Development of disease-modifying therapies for multiple sclerosis, such as monoclonal antibody-based cell depletion therapies, has been successful in eliminating pathological immune cell components and promoting the reconstitution of a healthy immune system.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Lucia Morales, Jesus M. Paramio
Summary: Bladder cancer presents a challenging problem in Oncology due to its high incidence and progression, leading to exploration of new avenues in its management. While immune checkpoint blockade inhibitors represent an unprecedented advance, the fraction of patients benefiting from them is limited. Cell-based therapies are promising tools for controlling solid tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Immunology
Guangwen Wang, Wenshi Wang
Summary: GBM is a highly treatment-resistant tumor with a poor prognosis, and it has proven to be resistant to both traditional and newer immunotherapies. The need for innovative and efficient treatment strategies is urgent. This review provides a comprehensive overview of various cell therapies currently being used to treat GBM, discussing their efficacy, safety, mechanisms, and challenges, with the aim of identifying the next-generation immunotherapeutic approach to eliminate this dreadful disease.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Bao Liu, Qifeng Ji, Ying Cheng, Miao Liu, Bangle Zhang, Qibing Mei, Daozhou Liu, Siyuan Zhou
Summary: The study successfully developed a novel targeted drug delivery system for enhancing immunotherapy of drug-resistant GBM and demonstrated its significant inhibitory effect on tumor growth and prolonged survival time in mice.
JOURNAL OF NANOBIOTECHNOLOGY
(2022)
Article
Oncology
Regina M. Young, Nils W. Engel, Ugur Uslu, Nils Wellhausen, Carl H. June
Summary: CD19 and BCMA-directed CAR T cells have shown remarkable efficacy in treating certain hematologic malignancies, but there are still unmet treatment needs. Next-generation CAR T cells will incorporate gene engineering and synthetic biology to improve functionality and persistence, and reduce treatment-related toxicities. Combining autologous CAR T cells with allogeneic cell treatment strategies targeting the tumor microenvironment will expand the impact of CAR T-cell therapies.
Review
Biochemistry & Molecular Biology
Karolina Stachyra, Monika Dudzisz-Sledz, Elzbieta Bylina, Anna Szumera-Cieckiewicz, Mateusz J. Spalek, Ewa Bartnik, Piotr Rutkowski, Anna M. Czarnecka
Summary: Merkel cell carcinoma is a rare and highly aggressive skin cancer that develops in sun-exposed areas. It can be categorized into viral positive and viral negative types, with the latter having a high mutation burden and abnormal gene expression. Surgical excision is the main treatment for MCC, while radiotherapy is effective but can lead to chemoresistance. Immunotherapy has become the standard first-line therapy for advanced MCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Immunology
Eunju Shin, Seong Ho Bak, Taeho Park, Jin Woo Kim, Suk-Ran Yoon, Haiyoung Jung, Ji-Yoon Noh
Summary: Gene-engineered immune cell therapies, particularly using CAR-T cells, have significantly impacted cancer treatment. However, there are limitations in targeting a broader range of cancer types. NK cells, a type of innate immune cells, offer a unique biology and can be genetically engineered to serve as a source for immune cell therapies. NK cell-based therapies, including NK cells, CAR-NK cells, and antibodies stimulating NK cell cytotoxicity, have emerged as promising approaches for various cancers. This review provides an overview of NK cell characteristics and discusses diseases that could benefit from NK-based therapies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Songshan Feng, Xisong Liang, Jing Li, Zeyu Wang, Hao Zhang, Ziyu Dai, Peng Luo, Zaoqu Liu, Jian Zhang, Xiaoxiong Xiao, Quan Cheng
Summary: Immunogenic cell death (ICD) is an important factor in tumor progression and therapeutic response. This study identifies ICD-related genes and constructs a risk signature that can predict prognosis and response to immune checkpoint blockade (ICB) treatment in glioblastoma (GBM) patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Mark Gurney, Michael O'Dwyer
Summary: CAR-NK cells, as an alternative cell therapy, offer advantages such as rapid availability and potentially fewer side effects, making them particularly suitable for the treatment of acute myeloid leukemia (AML). Research indicates that this therapy has the potential to be a new option for AML treatment.
Review
Immunology
Ya-Jui Lin, Caren Yu-Ju Wu, Janet Yuling Wu, Michael Lim
Summary: Glioblastoma is a highly aggressive glioma with resistance to immunotherapy, primarily due to the unique immune environment. Myeloid cells play a significant role in the glioma microenvironment and reprogramming them has emerged as a revolutionary immunotherapy for glioma treatment. This article provides a detailed classification and analysis of myeloid cells in glioma TME, aiming to offer new insights and therapeutic approaches for improving treatment efficacy in glioma patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Magdi Elsallab, Marcela V. Maus
Summary: Chimeric antigen receptor (CAR) T cells are revolutionizing the treatment of hematological malignancies. The current autologous and central manufacturing approach presents challenges in meeting the growing demand. Distributed manufacturing with advanced technologies is crucial to increase capacity and ensure uniform product quality. Expanded role of accreditation bodies and regulatory amendments are also necessary to support this model.
NATURE BIOTECHNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Romy Boettcher-Loschinski, Judit Rial Saborido, Martin Boettcher, Sascha Kahlfuss, Dimitrios Mougiakakos
Summary: T-cell-based approaches are increasingly important in cancer treatment, and the relationship between immune cell metabolism and immunotherapy success is crucial. Excessive exposure of T cells to fatty acids, known as lipotoxicity, can have detrimental effects in the context of an altered lipid tumor microenvironment. Understanding T cell-related lipotoxicity and developing potential therapeutic approaches is of great importance.
Review
Immunology
Hongwen Li, Wenting Song, Zhaoming Li, Mingzhi Zhang
Summary: CAR-NK cell therapy represents a promising strategy in the treatment of malignant tumors, with advantages over CAR-T cell therapy, but still faces challenges and limitations.
FRONTIERS IN IMMUNOLOGY
(2022)